Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL LIQUI-GELS vs 8-HOUR BAYER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Mild to moderate pain,Primary dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Fever reduction,Migraine (off-label)
Relief of pain, fever, and inflammation,Reduction of risk of myocardial infarction in patients with previous MI or unstable angina,Prevention of recurrent ischemic stroke or transient ischemic attack
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics).
Primarily hepatic via CYP2C9, with minor pathways including glucuronidation and CYP2C8. Metabolites are inactive.
Hepatic hydrolysis by esterases to salicylic acid, which is primarily conjugated in the liver via glucuronidation and glycine conjugation (salicyluric acid), with minor oxidation by cytochrome P450 (CYP2C9) to gentisic acid.
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile.
Approximately 99% bound to albumin.
80-90% bound to albumin; binding is concentration-dependent and saturable.
0.1 to 0.2 L/kg. Low Vd reflects extensive protein binding and limited tissue distribution.
0.15-0.2 L/kg for salicylate; distributes into synovial fluid, CNS, and placental tissues; Vd increases in acidosis.
Oral bioavailability of ibuprofen from Liqui-Gels is approximately 85-90% due to first-pass metabolism.
Oral: Approximately 100% for immediate-release, but extended-release may have slightly reduced absorption (relative bioavailability 85-90% compared to immediate-release).
e GFR 30–59 m L/min: maximum 800 mg/day in divided doses. e GFR <30 m L/min: contraindicated.
Avoid in severe renal impairment (Cr Cl <30 m L/min). Use with caution and monitor for bleeding in moderate impairment. Reduce dose or extend interval.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50% and monitor. Class C: avoid use.
Avoid in severe hepatic impairment. Use with caution in moderate impairment; monitor liver function.
Children ≥12 years: 200 mg orally every 4–6 hours, max 800 mg/day. Children <12 years: use weight-based ibuprofen (5–10 mg/kg/dose, max 40 mg/kg/day) not with Liqui-Gels formulation.
Not recommended in children <12 years for viral infections due to Reye's syndrome risk (contraindicated).
Start at lowest effective dose; maximum 800 mg/day due to increased risk of GI and renal adverse effects.
Increased risk of GI bleeding and renal impairment; use lowest effective dose, monitor renal function and signs of bleeding.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
None
Increased risk of gastrointestinal adverse events including bleeding, ulceration, and perforation; use lowest effective dose for shortest duration; avoid in patients with advanced renal disease; may cause hypertension or worsening of pre-existing hypertension; caution in patients with asthma, coagulation disorders, or fluid retention.
Increased risk of gastrointestinal bleeding and ulceration; Reye syndrome in children with viral illness; Hemorrhagic stroke risk with high doses; Impaired renal function in predisposed patients; Bronchospasm in aspirin-sensitive asthma; Anaphylactic reactions; Use caution in patients with hepatic impairment or G6PD deficiency.
Hypersensitivity to ibuprofen or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; history of gastrointestinal bleeding or perforation related to NSAIDs; severe heart failure.
Known hypersensitivity to NSAIDs or aspirin; Active peptic ulcer disease or GI bleeding; Severe renal impairment (e GFR <30 m L/min); Hemorrhagic diathesis; Children with viral infection (Reye syndrome); Third trimester of pregnancy; Severe hepatic impairment.
Alcohol increases risk of GI bleeding. No specific food restrictions; however, taking with high-fat meals may delay absorption but reduces GI irritation.
Avoid alcohol; may increase risk of gastrointestinal bleeding. No specific food restrictions, but taking with food can reduce gastric irritation. Avoid high-dose vitamin C supplements as they may increase salicylate levels.
First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects. Second trimester: Generally considered safer; however, avoid prolonged use. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment.
First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arteriosus, oligohydramnios, and increased risk of maternal and fetal bleeding. High doses may cause constriction of ductus arteriosus in utero and persistent pulmonary hypertension in newborn.
Ibuprofen is excreted in breast milk in low concentrations (M/P ratio approximately 0.01). Considered compatible with breastfeeding by the AAP. Use lowest effective dose for shortest duration.
Small amounts of aspirin are excreted in breast milk. M/P ratio not established. Use with caution in breastfeeding women; avoid high doses due to risk of Reye's syndrome in infants and potential for adverse effects on platelet function.
No specific dose adjustment required based on pharmacokinetic changes. Use lowest effective dose for shortest duration. Avoid in third trimester.
Pregnancy increases clearance of aspirin; however, dose adjustments are not routinely recommended due to narrow therapeutic index. Use lowest effective dose for shortest duration. Avoid in third trimester.
Advil Liqui-Gels contain solubilized ibuprofen, allowing for faster absorption (onset ~20-30 min) compared to solid tablets. The liquid-filled gel capsule may cause more gastrointestinal distress in sensitive patients; administer with food. Avoid in patients with severe heart failure, history of GI bleed, or after coronary artery bypass grafting. Monitor renal function in elderly or dehydrated patients. Use lowest effective dose for shortest duration.
8-Hour Bayer is enteric-coated aspirin designed for extended release, reducing gastrointestinal irritation. Onset of action is delayed; not suitable for acute pain or rapid antiplatelet effect. Use with caution in patients with history of peptic ulcer disease or on anticoagulants. Monitor renal function in elderly or dehydrated patients. Avoid in children with viral illness due to Reye's syndrome risk.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day unless directed by a doctor.,Swallow whole; do not crush, chew, or break the capsule.,Avoid alcohol while taking this medication.,Stop and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (e.g., black/tarry stools).,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Do not take with other NSAIDs (e.g., aspirin, naproxen).
Take with a full glass of water; do not crush or chew the tablet.,Do not use within 7 days before surgery due to bleeding risk.,If used for pain, consult a doctor if symptoms persist for more than 10 days.,Avoid alcohol while taking this medication to reduce stomach bleeding risk.,Seek medical attention for signs of bleeding (black stools, blood in vomit).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL LIQUI-GELS vs 8-HOUR BAYER, answered by our medical review team.
ADVIL LIQUI-GELS is a NSAID that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.. 8-HOUR BAYER is a NSAID that works by Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL LIQUI-GELS and 8-HOUR BAYER depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL LIQUI-GELS is: 200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.. The standard adult dose of 8-HOUR BAYER is: 325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL LIQUI-GELS and 8-HOUR BAYER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL LIQUI-GELS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects. Second trimester: Generally considered safer; however, avoid prolonged use. Third tri. 8-HOUR BAYER is classified as Category C. First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arte. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.